Pioneering ion channel discoveries and treatments for rare CNS disorders
The promise of a new and better class of medicines for patients
Our lead clinical programmes build on our knowledge of the novel Kv3 family of potassium channels. AUT00206 is a very promising clinical-stage Kv3 modulator for the treatment of Fragile X syndrome, where we have FDA Orphan Drug Designation. AUT00201 is a potent, clinical-stage Kv3 modulator for the treatment of rare epilepsy syndromes.
Autifony’s preclinical-stage assets targeting Kv3 channels show huge potential to treat a broader range of CNS indications such as schizophrenia and age-related hearing loss.
Our early-stage programmes are focused on other novel ion channel targets with the potential to treat CNS neurodegenerative and hyperexcitability disorders.